Login / Signup

Guselkumab, a Selective Interleukin-23 p19 Subunit Inhibitor, Resolves Dactylitis in Patients With Active Psoriatic Arthritis: Pooled Results Through Week 52 From Two Phase 3 Studies.

Dennis McGonagleIain B McInnesAtul A DeodharLarissa Valor-MéndezMay ShawiSoumya D ChakravartyAlexa P KollmeierXie L XuShihong ShengStephen XuChristopher T RitchlinProton RahmanPhillip J Mease
Published in: ACR open rheumatology (2023)
Through 1 year, approximately 75% of guselkumab-randomized patients had complete resolution of dactylitis; patients exhibiting resolution were more likely to achieve other important clinical outcomes. Given the high burden of dactylitis, resolution may be associated with better long-term patient outcomes.
Keyphrases
  • end stage renal disease
  • ejection fraction
  • newly diagnosed
  • prognostic factors
  • single molecule
  • randomized controlled trial
  • clinical trial
  • patient reported outcomes
  • open label
  • risk factors
  • phase iii
  • study protocol